<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891735</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4579g</org_study_id>
    <secondary_id>GX01511</secondary_id>
    <nct_id>NCT00891735</nct_id>
  </id_info>
  <brief_title>A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)</brief_title>
  <acronym>HARBOR</acronym>
  <official_title>A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the
      efficacy and safety of ranibizumab injection administered intravitreally to patients with
      choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
      Results are presented for the first 12 months of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Ranibizumab Injections up to But Not Including Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness &lt; 270 µm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</measure>
    <time_frame>Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</time_frame>
    <description>Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</measure>
    <time_frame>Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</time_frame>
    <description>Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm^2.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1097</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5 mg monthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab 2.0 mg monthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5 mg as-needed (pro re nata [PRN])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab 2.0 mg as-needed (pro re nata [PRN])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Sterile solution for intravitreal injection.</description>
    <arm_group_label>Ranibizumab 0.5 mg monthly</arm_group_label>
    <arm_group_label>Ranibizumab 2.0 mg monthly</arm_group_label>
    <arm_group_label>Ranibizumab 0.5 mg as-needed (pro re nata [PRN])</arm_group_label>
    <arm_group_label>Ranibizumab 2.0 mg as-needed (pro re nata [PRN])</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For sexually active women of childbearing potential, agreement to the use of an
             appropriate form of contraception (or abstinence) for the duration of the study.

        Ocular Inclusion Criteria (Study Eye)

          -  Best corrected visual acuity (BCVA), using Early Treatment Diabetic Retinopathy Study
             (ETDRS) charts, of 20/40−20/320 (Snellen equivalent).

          -  Choroidal neovascularization (CNV) lesions with classic CNV component, occult CNV, or
             with some classic CNV component were permissible.

          -  Total area of lesion &lt; 12 disc area or 30.48 mm^2.

        Exclusion Criteria:

          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for
             age-related macular degeneration (AMD) in the study eye.

          -  Prior treatment with Visudyne(R), external-beam radiation therapy, or transpupillary
             thermotherapy (TTT) in the study eye.

          -  Previous intravitreal drug delivery (eg, intravitreal corticosteroid injection,
             anti-angiogenic drugs, or device implantation) in the study eye.

          -  Previous treatment or participation in a clinical trial involving anti-angiogenic
             drugs (Avastin(R), anecortave acetate, protein kinase C inhibitors, etc), in the
             non-study eye within 3 months of Day 0 (first day of treatment). The patient may not
             have received Lucentis(R) or Macugen(R) in the non-study eye within 7 days of Day 0.

          -  Treatment with Visudyne(R) in the non-study eye &lt; 7 days preceding Day 0.

          -  Subretinal hemorrhage in the study eye that involves the center of the fovea, if the
             size of the hemorrhage is either &gt; 50% of the total area of the lesion or &gt; 1 disc
             area (2.54 mm^2) in size.

          -  Subfoveal fibrosis or atrophy in the study eye.

          -  CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or
             pathologic myopia.

          -  Retinal pigment epithelial tear involving the macula in the study eye.

          -  Any concurrent intraocular condition in the study eye (eg, cataract or diabetic
             retinopathy) that, in the opinion of the investigator, could either: Require medical
             or surgical intervention during the 24-month study period to prevent or treat visual
             loss that might result from that condition; or if allowed to progress untreated, could
             likely contribute to loss of at least 2 Snellen equivalent lines of best corrected
             visual acuity (BCVA) over the 24-month study period.

          -  Uncontrolled blood pressure.

          -  Atrial fibrillation not managed by patient's primary care physician or cardiologist
             within 3 months of screening visit.

          -  History of stroke within the last 3 months of screening visit.

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use an investigational drug or that might affect interpretation of
             the results of the study or renders the patient at high risk for treatment
             complications.

          -  Current treatment for active systemic infection.

          -  Active malignancy.

          -  History of allergy to fluorescein, not amenable to treatment.

          -  Previous participation in any studies of investigational drugs within 1 month
             preceding Day 0 (excluding vitamins and minerals).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chico</city>
        <state>California</state>
        <zip>95973</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <zip>08225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vauxhall</city>
        <state>New Jersey</state>
        <zip>07088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shirley</city>
        <state>New York</state>
        <zip>11967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntingdon Valley</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Casper</city>
        <state>Wyoming</state>
        <zip>82601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2009</study_first_posted>
  <results_first_submitted>September 18, 2012</results_first_submitted>
  <results_first_submitted_qc>December 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2013</results_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lucentis</keyword>
  <keyword>AMD</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Subfoveal neovascular age-related macular degeneration</keyword>
  <keyword>Wet AMD</keyword>
  <keyword>Macular degeneration</keyword>
  <keyword>Ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab 0.5 mg Monthly</title>
          <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Ranibizumab 2.0 mg Monthly</title>
          <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
        </group>
        <group group_id="P3">
          <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
          <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
        </group>
        <group group_id="P4">
          <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
          <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="274"/>
                <participants group_id="P3" count="275"/>
                <participants group_id="P4" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="258"/>
                <participants group_id="P3" count="263"/>
                <participants group_id="P4" count="258"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician's decision to withdraw patient</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient's decision to withdraw</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab 0.5 mg Monthly</title>
          <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Ranibizumab 2.0 mg Monthly</title>
          <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
          <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
        </group>
        <group group_id="B4">
          <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
          <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="275"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="275"/>
            <count group_id="B4" value="273"/>
            <count group_id="B5" value="1097"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.8" spread="8.4"/>
                    <measurement group_id="B2" value="79.3" spread="8.3"/>
                    <measurement group_id="B3" value="78.5" spread="8.3"/>
                    <measurement group_id="B4" value="78.3" spread="8.3"/>
                    <measurement group_id="B5" value="78.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="163"/>
                    <measurement group_id="B4" value="156"/>
                    <measurement group_id="B5" value="651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12</title>
        <description>BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg Monthly</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab 2.0 mg Monthly</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12</title>
          <description>BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.</description>
          <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="13.3"/>
                    <measurement group_id="O2" value="9.2" spread="14.6"/>
                    <measurement group_id="O3" value="8.2" spread="13.3"/>
                    <measurement group_id="O4" value="8.6" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ranibizumab Injections up to But Not Including Month 12</title>
        <time_frame>Baseline to Month 12</time_frame>
        <population>All treated patients. Observed data were used with no imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg Monthly</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab 2.0 mg Monthly</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ranibizumab Injections up to But Not Including Month 12</title>
          <population>All treated patients. Observed data were used with no imputation.</population>
          <units>Injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="1.8"/>
                    <measurement group_id="O2" value="11.2" spread="2.1"/>
                    <measurement group_id="O3" value="7.7" spread="2.7"/>
                    <measurement group_id="O4" value="6.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12</title>
        <description>BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg Monthly</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab 2.0 mg Monthly</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12</title>
          <description>BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.</description>
          <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="28.9" upper_limit="40.2"/>
                    <measurement group_id="O2" value="36.1" lower_limit="30.4" upper_limit="41.8"/>
                    <measurement group_id="O3" value="30.2" lower_limit="24.8" upper_limit="35.6"/>
                    <measurement group_id="O4" value="33.0" lower_limit="27.4" upper_limit="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12</title>
        <description>VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart.</description>
        <time_frame>Month 12</time_frame>
        <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg Monthly</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab 2.0 mg Monthly</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12</title>
          <description>VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart.</description>
          <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="46.5" upper_limit="58.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="44.1" upper_limit="55.9"/>
                    <measurement group_id="O3" value="46.2" lower_limit="40.3" upper_limit="52.1"/>
                    <measurement group_id="O4" value="43.6" lower_limit="37.7" upper_limit="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12</title>
        <description>The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness &lt; 270 µm.</description>
        <time_frame>Month 12</time_frame>
        <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg Monthly</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab 2.0 mg Monthly</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12</title>
          <description>The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness &lt; 270 µm.</description>
          <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="2.5" upper_limit="7.7"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.1" upper_limit="8.6"/>
                    <measurement group_id="O3" value="2.9" lower_limit="0.9" upper_limit="4.9"/>
                    <measurement group_id="O4" value="4.8" lower_limit="2.2" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</title>
        <description>Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT).</description>
        <time_frame>Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</time_frame>
        <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg Monthly</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab 2.0 mg Monthly</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</title>
          <description>Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT).</description>
          <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-104.9" spread="130.3"/>
                    <measurement group_id="O2" value="-84.9" spread="111.3"/>
                    <measurement group_id="O3" value="-103.5" spread="141.3"/>
                    <measurement group_id="O4" value="-100.6" spread="123.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-141.5" spread="137.5"/>
                    <measurement group_id="O2" value="-128.6" spread="133.3"/>
                    <measurement group_id="O3" value="-132.6" spread="148.2"/>
                    <measurement group_id="O4" value="-146.0" spread="144.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-152.5" spread="142.4"/>
                    <measurement group_id="O2" value="-140.3" spread="131.1"/>
                    <measurement group_id="O3" value="-142.9" spread="141.6"/>
                    <measurement group_id="O4" value="-156.9" spread="145.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-157.0" spread="143.8"/>
                    <measurement group_id="O2" value="-147.9" spread="134.3"/>
                    <measurement group_id="O3" value="-154.5" spread="147.9"/>
                    <measurement group_id="O4" value="-164.9" spread="144.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-164.0" spread="146.6"/>
                    <measurement group_id="O2" value="-151.8" spread="143.3"/>
                    <measurement group_id="O3" value="-142.7" spread="153.6"/>
                    <measurement group_id="O4" value="-159.7" spread="148.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-162.0" spread="150.0"/>
                    <measurement group_id="O2" value="-149.2" spread="144.0"/>
                    <measurement group_id="O3" value="-147.5" spread="151.9"/>
                    <measurement group_id="O4" value="-159.1" spread="149.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-164.5" spread="151.8"/>
                    <measurement group_id="O2" value="-153.1" spread="144.8"/>
                    <measurement group_id="O3" value="-153.5" spread="147.1"/>
                    <measurement group_id="O4" value="-157.8" spread="155.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-172.0" spread="150.5"/>
                    <measurement group_id="O2" value="-163.3" spread="142.6"/>
                    <measurement group_id="O3" value="-161.2" spread="152.3"/>
                    <measurement group_id="O4" value="-172.4" spread="148.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</title>
        <description>Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT).</description>
        <time_frame>Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</time_frame>
        <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg Monthly</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab 2.0 mg Monthly</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12</title>
          <description>Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT).</description>
          <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.80"/>
                    <measurement group_id="O2" value="-0.80" spread="0.76"/>
                    <measurement group_id="O3" value="-0.72" spread="0.87"/>
                    <measurement group_id="O4" value="-0.81" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="1.06"/>
                    <measurement group_id="O2" value="-1.30" spread="1.15"/>
                    <measurement group_id="O3" value="-1.16" spread="1.03"/>
                    <measurement group_id="O4" value="-1.38" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.17"/>
                    <measurement group_id="O2" value="-1.49" spread="1.31"/>
                    <measurement group_id="O3" value="-1.30" spread="1.13"/>
                    <measurement group_id="O4" value="-1.47" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.25"/>
                    <measurement group_id="O2" value="-1.51" spread="1.32"/>
                    <measurement group_id="O3" value="-1.43" spread="1.33"/>
                    <measurement group_id="O4" value="-1.55" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.22"/>
                    <measurement group_id="O2" value="-1.56" spread="1.31"/>
                    <measurement group_id="O3" value="-1.31" spread="1.24"/>
                    <measurement group_id="O4" value="-1.48" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.25"/>
                    <measurement group_id="O2" value="-1.61" spread="1.34"/>
                    <measurement group_id="O3" value="-1.35" spread="1.33"/>
                    <measurement group_id="O4" value="-1.48" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="1.41"/>
                    <measurement group_id="O2" value="-1.67" spread="1.34"/>
                    <measurement group_id="O3" value="-1.35" spread="1.31"/>
                    <measurement group_id="O4" value="-1.48" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="1.31"/>
                    <measurement group_id="O2" value="-1.66" spread="1.37"/>
                    <measurement group_id="O3" value="-1.41" spread="1.36"/>
                    <measurement group_id="O4" value="-1.49" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12</title>
        <description>The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm^2.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg Monthly</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab 2.0 mg Monthly</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
            <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12</title>
          <description>The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm^2.</description>
          <population>Intent-to-treat population: All randomized patients. Missing data were imputed using the last observation carried forward method.</population>
          <units>Disc area units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in the total area of CNV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="2.40"/>
                    <measurement group_id="O2" value="-2.42" spread="2.38"/>
                    <measurement group_id="O3" value="-1.74" spread="2.22"/>
                    <measurement group_id="O4" value="-1.98" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in the total area of CNV leakage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="2.39"/>
                    <measurement group_id="O2" value="-2.63" spread="2.34"/>
                    <measurement group_id="O3" value="-2.01" spread="2.28"/>
                    <measurement group_id="O4" value="-2.22" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from Baseline (first treatment day) through Month 12.</time_frame>
      <desc>Safety population: All patients who received at least 1 study treatment. Adverse events reported here include ocular adverse events in the study eye and fellow eye, as well as non-ocular adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab 0.5 mg Monthly</title>
          <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab 2.0 mg Monthly</title>
          <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 12 months.</description>
        </group>
        <group group_id="E3">
          <title>Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])</title>
          <description>Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.</description>
        </group>
        <group group_id="E4">
          <title>Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])</title>
          <description>Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 9 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Corneal oedema</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gastric antral vascular ectasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Large intestinal harmorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Breast infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Post procedural heamatoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Splenic marginal zone lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Tumour ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Somatic delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Thrombosis prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="250" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="239" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Detachment of retinal pigment epithelium</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="275"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Genentech, Inc.</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

